Category: BioTech

FB Nasdaq FB Facebook
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Discover’s Momentum Continues in 1Q

Discover Financial Service DFS reported net income of $673 million, or $1.33 per diluted share, for the first quarter of 2013. The narrow-moat company continued to generate strong momentum across business lines, increasing book value more than 5% during the quarter, and we may moderately increase our fair value estimate as we incorporate the quarter’s results and transfer coverage to a new analyst. In contrast … Continue reading Discover’s Momentum Continues in 1Q

John MeadyLeave a comment
BioTech, Finance

Biotech Stock in Focus: Bayer Continues Progress with Eylea

Bayer’s (BAYRY) has progressed well with its newly launched products in the last few quarters. Drugs like Eylea (Eye), Stivarga (oncology), Xarelto (anticoagulant), Xofigo (oncology) and Adempas (pulmonary hypertension) posted sales of €598 million in the first quarter and are expected to contribute around €2.8 billion in 2014. The company is looking to get these products approved for additional indications as well. Last week, Bayer … Continue reading Biotech Stock in Focus: Bayer Continues Progress with Eylea

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, software, Software, Tech IPO

China Telecom Reaps Efficiency Gains in 1Q After 3G Assets Acquisition

Carrier China Telecom CHA increased first-quarter revenue 15% year over year to CNY 78 billion ($12.6 billion) thanks to strong mobile service revenue and handset sales. EBITDA grew at a much faster pace of 36%, as the firm benefited from scale efficiencies on its 3G network after it acquired the assets from its parent at the end of December. We are maintaining our narrow economic … Continue reading China Telecom Reaps Efficiency Gains in 1Q After 3G Assets Acquisition

John MeadyLeave a comment
BioTech, Finance

Biotech Stocks Weekly Roundup

PRevious Few Days have been very eventful for the Biotech Stocks. Last week, earnings remained in focus with several companies reporting their second quarter results. While Amgen’s (AMGN) results remained impressive, Vertex (VRTX) posted a wider loss. Meanwhile, Regeneron (REGN) missed earnings expectations by a pretty wide margin though Eylea sales continued to impress. Among all this, the Ebola outbreak is also making headlines and … Continue reading Biotech Stocks Weekly Roundup

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, software, Software, Tech IPO

Investments in Mobile Weighed on First-Quarter Margins for Baidu; Shares Undervalued

Chinese search engine Baidu BIDU posted a 40% increase in first-quarter revenue that met our expectations, although margins came under pressure due to aggressive investments in mobile Internet. We believe these strategic investments behind product innovation, engineering talents, network infrastructure, and marketing campaigns are critical to fortifying Baidu’s competitiveness in the fastgrowing mobile Internet space over the longer term. We applaud management’s decision to accelerate … Continue reading Investments in Mobile Weighed on First-Quarter Margins for Baidu; Shares Undervalued

John MeadyLeave a comment
BioTech, Finance

Biotech Stock Update: Regeneron Misses on Earnings in Q2

Regeneron Pharmaceuticals’ (REGN) second quarter 2014 adjusted earnings (including stock-based compensation expense) of $1.89 per share were well short of the Consensus Estimate of $2.33. The company had earned $1.36 per share in the year-ago quarter. Results were impacted by higher costs. Including one-time items, earnings increased 3.8% to 82 cents per share. A higher tax rate affected results. Excluding stock based compensation expenses the … Continue reading Biotech Stock Update: Regeneron Misses on Earnings in Q2

Richard Atkins